European Journal of Clinical Pharmacology

, Volume 68, Issue 5, pp 723–733

Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase

  • Richard A. Larson
  • Ophelia Q. P. Yin
  • Andreas Hochhaus
  • Giuseppe Saglio
  • Richard E. Clark
  • Hirohisa Nakamae
  • Neil J. Gallagher
  • Eren Demirhan
  • Timothy P. Hughes
  • Hagop M. Kantarjian
  • Philipp D. le Coutre
Pharmacokinetics and Disposition

DOI: 10.1007/s00228-011-1200-7

Cite this article as:
Larson, R.A., Yin, O.Q.P., Hochhaus, A. et al. Eur J Clin Pharmacol (2012) 68: 723. doi:10.1007/s00228-011-1200-7

Abstract

Purpose

We investigated the population pharmacokinetics and exposure-response relationship of nilotinib in patients with newly diagnosed chronic myeloid leukemia (CML) in chronic phase.

Methods

Nilotinib was given at 300 mg or 400 mg twice daily. Serum concentration data (sparse and full pharmacokinetic profiles) were obtained from 542 patients over 12 months. A population pharmacokinetic analysis was performed using nonlinear mixed-effect modeling. Exposure-response relationships were explored graphically or using logistic regression models.

Results

Nilotinib concentrations were stable over 12 months. Patients in the 400 mg twice-daily arm had an 11.5% higher exposure than did those in the 300 mg twice-daily arm, and the relative bioavailability of nilotinib 400 mg twice daily was 0.84 times that of 300 mg twice daily. Patient demographics did not significantly affect nilotinib pharmacokinetics. The occurrence of all-grade total bilirubin elevation was significantly higher in patients with higher nilotinib exposure, and a positive correlation was also observed between nilotinib exposure and QTcF change on electrocardiograms from baseline. There was no significant relationship between nilotinib exposure and major molecular response at 12 months.

Conclusions

There is a less than proportional dose-exposure relationship between nilotinib 300 mg and 400 mg twice-daily doses. Blood level testing is unlikely to play an important role in the general management of patients with newly diagnosed CML treated with nilotinib.

Keywords

Nilotinib Population pharmacokinetics Exposure-response relationship Chronic myeloid leukemia 

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Richard A. Larson
    • 1
  • Ophelia Q. P. Yin
    • 2
    • 11
  • Andreas Hochhaus
    • 3
  • Giuseppe Saglio
    • 4
  • Richard E. Clark
    • 5
  • Hirohisa Nakamae
    • 6
  • Neil J. Gallagher
    • 7
  • Eren Demirhan
    • 2
  • Timothy P. Hughes
    • 8
  • Hagop M. Kantarjian
    • 9
  • Philipp D. le Coutre
    • 10
  1. 1.University of ChicagoChicagoUSA
  2. 2.Novartis Pharmaceuticals CorporationFlorham ParkUSA
  3. 3.Universitätsklinikum JenaJenaGermany
  4. 4.University of TurinOrbassanoItaly
  5. 5.Royal Liverpool University HospitalLiverpoolUK
  6. 6.Osaka City UniversityOsakaJapan
  7. 7.Novartis Pharma AGBaselSwitzerland
  8. 8.SA Pathology Royal Adelaide HospitalAdelaideAustralia
  9. 9.The University of Texas M. D. Anderson Cancer CenterHoustonUSA
  10. 10.Campus Virchow KlinikumCharité – Universitätsmedizin BerlinBerlinGermany
  11. 11.Oncology Clinical PharmacologyNovartis Pharmaceuticals CorporationFlorham ParkUSA

Personalised recommendations